Pull This Up Tonight: (QNTM) Is Back On Our Radar For Tomorrow—Last Time It Moved Approx. 566%

*Sponsored Market Crux Exclusive Profile For Thursday 3/27/2025—Just Announced! Quantum BioPharma (NASDAQ: QNTM) Just Landed On Our Radar For Tomorrow Morning. And Here’s Why… Since The Last Time We Covered (QNTM) It Made An Approx. 566% Move From $2.70 To $18.00 In Under Two And A Half Months. Fewer Than 1.6M Publicly Available Shares Place (QNTM) In Ultra Low Float Territory With Limited Supply. (QNTM) Logged Session-To-Session Moves Of Approximately 145%, 213%, And 111% In Recent Months. (QNTM) Is Trending Above All Major Moving Averages And Triggered 17 Bullish Signals On TradingView. Take A Look At (QNTM) Before Tomorrow Morning… March 26, 2025 Dear Reader, Following today’s profile that got off to an early start—moving approximately 36% before the bell even rang—we’re now turning our attention to one of my favorite sectors. Biopharma. It’s one of the most dynamic industries on the market—where a single breakthrough can elevate a quiet player into the spotlight, seemingly overnight. That’s why tomorrow, Quantum BioPharma (NASDAQ: QNTM) will be topping our watchlist. And now, with multiple catalysts in motion, it may not stay under the radar much longer. Momentum Is Already Building Since the last time we brought Quantum BioPharma (NASDAQ: QNTM) to your radar, it hasn’t exactly stood still. It moved approximately 566%, from around $2.70 on 12/20/2024 to $18.00 by 2/6/2025. Including an approx. 506% move in under 4 days. Yet even with that kind of move, Quantum BioPharma (NASDAQ: QNTM) appears to be one of those companies that still flies under the radar—with a market cap just around $15M.  Historically, this is the range where lesser-known names have made some of their biggest moves—especially when the right catalyst hits. And technically?  It’s still flashing strength. Quantum BioPharma (NASDAQ: QNTM) is currently trending above every major moving average tracked by Barchart, including: Late this afternoon, Quantum BioPharma (NASDAQ: QNTM) lit up 17 Bullish Signals, including the “Momentum Indicator” on TradingView’s technical analysis dashboard—adding confidence as we head into tomorrow’s open. But there’s another element that can’t be ignored… A Float This Thin Can Move Fast… One of the most important dynamics to understand here is supply—or more accurately, the lack of it. As of now, there’s less than 1.6M shares of Quantum BioPharma (NASDAQ: QNTM) listed as publicly available in its float.  That’s considered ultra low float territory, where even modest interest can create sharp moves simply due to scarcity. And this isn’t theoretical. It’s already played out in recent sessions. Case in Point: Look at These Recent Moves We’ve seen multiple breakout-style moves—some in under 24 hours, others across just a few trading days. Approx. 145% move in under 24 hours From $2.97 on Mon 02/03/2025 to $7.28 on Tue 02/04/2025 Approx. 213% move in under 24 hours From $5.75 on Wed 02/05/2025 to $18.00 on Thu 02/06/2025 Approx. 86% move from session to session From $4.60 on Fri 03/14/2025 to $8.60 on Mon 03/17/2025 Approx. 111% move in under 24 hours From $4.76 on Tue 02/04/2025 to $10.05 on Wed 02/05/2025 Approx. 506% move in under 4 days From $2.97 on Mon 02/03/2025 to $18.00 on Thu 02/06/2025 With momentum building and a float this tight, it’s no surprise Quantum BioPharma (NASDAQ: QNTM) is topping our watchlist tomorrow. So let’s break down exactly what this company is building—and why it’s starting to turn heads across both the consumer health and biopharma worlds. Focused on Urgency, Not Hype… Quantum BioPharma (NASDAQ: QNTM) has zeroed in on two challenges that carry both human and economic weight: The societal burden of alcohol misuse, where traditional treatment and recovery tools have struggled to keep up The widespread impact of degenerative neurological conditions—especially multiple sclerosis (MS), where current therapies often fail to halt progression, let alone repair damage These aren’t theoretical pain points.  These are real-world problems that impact families, frontline healthcare, and national budgets. Rather than spread thin across broad categories, Quantum BioPharma (NASDAQ: QNTM) is going deep—with advanced R&D, a streamlined business model, and a capital-efficient approach that leverages partnerships to move fast. The Consumer Launch That’s Already Making Progress: unbuzzd™ Quantum BioPharma (NASDAQ: QNTM) holds a 25.71% equity stake in Celly Nutrition, the team behind unbuzzd™—a fast-acting alcohol detox supplement that officially launched in 2024. Here’s what stands out: Scientifically formulated and delivered in a fast-absorbing powder stick Designed to accelerate alcohol metabolism and restore alertness within 15–30 minutes A double-blind, placebo-controlled clinical trial completed in early 2025 showed significant reductions in perceived impairment and blood alcohol concentration (BrAC) Distribution is already scaling across direct-to-consumer channels, with retail and foodservice next on deck Celly Nutrition has engaged a leading New York investment bank to explore a potential public listing Quantum BioPharma (NASDAQ: QNTM)’s structure allows it to benefit from unbuzzd™ without shouldering the marketing or retail rollout. It receives: A 7% royalty on all gross revenue from unbuzzd™ until the company receives $250 million A 3% royalty in perpetuity thereafter Full ownership of the rights for pharmaceutical and medical applications of the core formulation It’s a capital-light structure with built-in leverage—and momentum is building. Beyond the Consumer Market: rekvry™… Alcohol misuse isn’t just a personal issue. It sends millions to emergency rooms every year—yet most hospitals still rely on outdated or nonspecific treatments. That’s where rekvry™ comes in. Currently under development, rekvry™ is designed for acute settings like hospitals and trauma centers. Quantum holds 100% of the rights to all medical and pharmaceutical formulations of this asset. This adds depth to the alcohol recovery pipeline—one branch addressing lifestyle and consumer access, the other focused on critical care. On the Neurology Front: LUCID-21-302… Quantum BioPharma (NASDAQ: QNTM)’s therapeutic pipeline also includes a potentially groundbreaking approach to multiple sclerosis (MS)—a disease that affects nearly 1M people in the U.S. and 2.8M globally. Its most advanced candidate is LUCID-21-302, a new chemical entity (NCE) that targets demyelination, the root mechanism of MS. What makes it different? 14+ years of preclinical R&D Mouse model studies showed accelerated functional recovery and preserved myelin integrity Phase 1 trial (SAD/MAD) completed with no serious dr-ug-related adverse effects Phase 2 trial expected in Q1 2026 Notably, the therapy does not rely on immune suppression, breaking from the standard approach used in most MS treatments Quantum BioPharma (NASDAQ: QNTM) holds exclusive global rights to this compound—not just for MS, but for other demyelinating diseases as well. With the global MS market expected to grow sharply in the coming years, a non-immunosuppressive therapy with this profile stands to draw increasing attention.  A Leadership Team with Depth and Range This isn’t a team learning on the fly. Quantum BioPharma (NASDAQ: QNTM) is led by a mix of scientific, commercial, and operational veterans with a record of high-impact execution: Kevin Harrington – Original Shark Tank member and brand-builder with $6B+ in sales across global markets Dr. Lakshmi Kotra, PhD – A renowned medicinal chemist with a portfolio of successful dru-g development programs Dr. Eric Hoskins – Former Ontario Minister of Health with decades of experience in public healthcare systems Gerry David – The executive behind Celsius Holdings’ 35x rise in value during his leadership Zeeshan Saeed – Capital markets strategist and Quantum’s founding CEO Together, they bring experience across every part of the development-to-launch cycle—from lab to shelf, from regulatory filings to go-to-market partnerships. Built for Speed—and Structured to Scale… Quantum BioPharma (NASDAQ: QNTM)’s business model is designed for acceleration, not overhead. Instead of trying to control every piece of the commercialization process, the company retains key assets, builds partnerships, and shares upside through equity, royalties, and licensing. This includes: 100% ownership of pharmaceutical and medical rights for its alcohol health pipeline Exclusive worldwide patents for its MS therapeutic 25.71% equity stake in Celly Nutrition Royalties on gross revenue without operational cost drag In short, it’s a lean model built to unlock value without relying on a bloated infrastructure. What’s Coming Next… Several near-term milestones are already on the calendar, including: unbuzzd™ scaling into national retail and foodservice distribution Expanded e-commerce presence via TikTok Shop, iHerb, affiliate networks, and brand partnerships rekvry™ clinical planning and further development Potential IPO for Celly Nutrition Phase 2 trial for LUCID-21-302 in early 2026 Ongoing treasury diversification, including recent digital asset acquisitions The company is also actively expanding its visibility through new IR partnerships and media outreach. Recent Developments… March 26, 2025 – Celly Nutrition Expands unbuzzd™ Product Lineup for Retail Quantum BioPharma (NASDAQ: QNTM)’s licensee, Celly Nutrition, announced the expansion of its alcohol detox product, unbuzzd™, with new retail-ready formats designed for broader consumer access. The rollout includes updated packaging and display configurations to support placement at point-of-sale counters nationwide. Full announcement → March 20, 2025 – Further Diversification with $1.5M in Digital Assets Quantum BioPharma (NASDAQ: QNTM) disclosed an additional $1.5M purchase of B-T-C and other cry-pto-curren-cies, marking another step in its ongoing treasury diversification strategy. This builds on previous cry-pto acquisitions aimed at strengthening long-term fiscal flexibility. Full story → February 26, 2025 – Phase 1 Trial Completed for MS Dr-ug LUCID-21-302 Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of its Phase 1 Multiple Ascending Dose (MAD) trial for LUCID-21-302, its lead asset for demyelinating diseases. The study reported no serious dr-ug-related adverse events, paving the way for a Phase 2 trial expected to begin in 2026. Read more → However… Quantum BioPharma (NASDAQ: QNTM) isn’t built for headlines.  It’s built for traction. While the broader market keeps cycling through trends, Quantum BioPharma (NASDAQ: QNTM) is showcasing science-backed solutions for problems that aren’t going away—and doing it with a structure that emphasizes speed, flexibility, and capital discipline. Whether it’s accelerating alcohol metabolism, restoring function in neurodegenerative conditions, or simply outpacing larger peers with less drag—this is a company worth watching closely. Especially before everyone else does. 7 Reasons Why Quantum BioPharma (NASDAQ: QNTM) is Topping Our Watchlist Tomorrow Morning—Thursdsay 3/27/2025… 1. Recent Momentum Has Been Hard to Ignore: Since December 2024, (QNTM) moved from $2.70 to $18.00—an estimated 566% move, with one of those surges (approx. 506%) playing out in just four sessions. 2. Ultra Low Float: With fewer than 1.6M shares publicly available, (QNTM) sits in a range where supply is limited—and past moves show how quickly things can shift when attention builds. 3. Breakout Sessions: In recent months, (QNTM) has made session-to-session moves of approx. 145%, 213%, and 111%—showcasing how reactive it can be under the right conditions. 4. Strong Technical Confirmation: (QNTM) is trending above every major moving average tracked by Barchart, including its 5-day, 20-day, 50-day, and 200-day levels. It also triggered 17 bullish signals on TradingView, including the widely watched “Momentum Indicator.” 5. Advancing Products in Urgent Categories: (QNTM) is connected to real-world challenges—from alcohol misuse to degenerative neurological conditions—and holds an interest in multiple science-backed solutions, including a consumer detox formulation and a clinical-stage therapeutic for MS. 6. Multiple Catalysts Already in Motion: Recent developments include the completion of a Phase 1 trial for LUCID-21-302, a retail product expansion for unbuzzd™, and ongoing treasury diversification moves—all within the past month. 7. A Lean Model with Built-In Leverage: (QNTM) maintains full ownership of pharmaceutical and medical rights for its alcohol health pipeline, exclusive worldwide patents for its MS candidate, and a 25.71% equity stake in a potential IPO-bound consumer brand—all without absorbing the full cost burden of commercial execution. Take a Look at Quantum BioPharma (NASDAQ: QNTM) Before Tomorrow Morning… Quantum BioPharma (NASDAQ: QNTM) isn’t just moving—it’s executing. It’s advancing products tied to real-world health challenges, triggering technical strength across multiple platforms, and maintaining a lean structure that gives it room to maneuver.  Add in an ultra low float and a series of recent breakout sessions, and you’ve got a setup that deserves a closer look. Momentum has already made its mark—but with multiple potential catalysts still in play, there could be more ahead. We’ll have all eyes on (QNTM) tomorrow morning. Consider taking a look at (QNTM) before you go to sleep. Maybe even get up early and pull up (QNTM). I’ll follow up with you in the morning—keep an eye for my morning update. Have a good night. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Quantum BioPharma Ltd. (QNTM:US) (QNTM:CA) previously changed their company name and symbols from FSD Pharma Inc. (HUGE:US) (QNTM:CA). Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/26/2025 and ending on 03/31/2025 to publicly disseminate information about (QNTM:US) (QNTM:CA) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid forty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer of (QNTM:US) (QNTM:CA). Neither Headline Media LLC, TD Media LLC and their member own shares of (QNTM:US) (QNTM:CA). Please see important disclosure information here: https://marketcrux.com/disclosure/qntm/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice